Furthermore, disclosing the APOE genotype after careful and sufficient information distribution does not always result in adverse consequences (e.g., increased anxiety or depression levels) in clinical research settings (Green et al. 2009; Bemelmans et al. 2016; Alber et al. 2022). The gene discussed is APOE; the disease is depressive symptom measurement.